Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2020 June;72(3) > Minerva Urologica e Nefrologica 2020 June;72(3):321-31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Urologica e Nefrologica 2020 June;72(3):321-31

DOI: 10.23736/S0393-2249.20.03672-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The role of glycosaminoglycans in the management of chronic pelvic pain: a systematic review

Valerio IACOVELLI 1, 2, Daniele BIANCHI 3 , Simone PLETTO 4, Patrizio PACINI 4, Claudia FEDE SPICCHIALE 4, Enrico FINAZZI AGRÒ 1

1 Department of Surgical Sciences, Tor Vergata University, Rome, Italy; 2 Department of Urology, San Carlo di Nancy Hospital, Rome, Italy; 3 Department of Urology, Tor Vergata Polyclinic, Rome, Italy; 4 School of Specialization in Urology, Tor Vergata University, Rome, Italy



INTRODUCTION: Glycosaminoglycans (GAGs) are involved in the pathogenesis of several urologic chronic diseases. Thus, GAGs replenishment therapy is widely reported as a therapeutic tool for chronic pelvic pain (CPP) conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and prostate pain syndrome/chronic prostatitis. In this article we reviewed the current status of evidence on the clinic applications of glycosaminoglycans (GAGs) in the CPP.
EVIDENCE ACQUISITION: A literature search from inception was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement to identify clinical trials, randomized controlled trials, meta-analyses, and guidelines.
EVIDENCE SYNTHESIS: A total of 29 papers were identified regarding the use of GAGs in CPP.
CONCLUSIONS: GAGs replenishment therapy results are encouraging in chronic forms of pelvic pain even though well-powered randomized clinical trials are needed to better comprehend the exact role of this treatment.


KEY WORDS: Glycosaminoglycan; Administration, intravesical; Prostatitis; Cystitis, interstitial

top of page